Catalyst Pharmaceuticals, Inc. (CPRX)

Jul 15, 2026 - CPRX was delisted (reason: acquired by Angelini Pharma)

31.49

0.00 (0.00%)

Inactive · Last trade price on Jul 15, 2026

Catalyst Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	3,855	2,869	2,489	1,792	1,936	698
Market Cap Growth	45.11%	15.25%	38.90%	-7.42%	177.28%	101.66%
Enterprise Value	3,102	2,182	2,050	1,675	1,684	528
Last Close Price	31.49	23.34	20.87	16.81	18.60	6.77

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	18.20	13.39	15.19	25.10	23.30	17.68
Forward PE	15.69	15.48	15.38	14.13	14.98	13.97
PS Ratio	6.46	4.87	5.06	4.50	9.04	4.96
PB Ratio	3.80	3.01	3.42	4.62	6.44	3.38
P/TBV Ratio	4.33	3.49	4.36	9.25	7.22	3.38
P/FCF Ratio	18.52	13.75	10.40	-	18.26	11.76
P/OCF Ratio	18.51	13.75	10.38	12.48	16.68	11.56
PEG Ratio	1.26	1.31	1.15	-	-	-

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	5.20	3.70	4.17	4.21	7.86	3.75
EV/EBITDA Ratio	10.14	7.38	8.80	13.99	16.33	10.03
EV/EBIT Ratio	11.59	8.46	10.51	19.29	16.53	10.07
EV/FCF Ratio	14.90	10.46	8.57	-	15.88	8.89

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.00	0.00	0.00	0.01	0.01	0.02
Debt / EBITDA Ratio	0.01	0.01	0.01	0.03	0.04	0.08
Debt / FCF Ratio	0.01	0.01	0.01	-	0.04	0.07
Net Debt / Equity Ratio	-0.74	-0.74	-0.71	-0.35	-0.98	-0.90
Net Debt / EBITDA Ratio	-2.46	-2.39	-2.21	-1.12	-2.86	-3.56
Net Debt / FCF Ratio	-3.62	-3.39	-2.15	2.44	-2.78	-3.15
Asset Turnover	0.58	0.60	0.74	0.94	0.70	0.66
Inventory Turnover	3.48	3.53	4.63	12.93	7.38	6.20
Quick Ratio	6.70	5.69	4.84	2.52	5.37	7.32
Current Ratio	7.10	6.08	5.17	2.88	5.57	7.76
Return on Equity (ROE)	24.50%	25.49%	29.38%	20.75%	32.76%	20.98%
Return on Assets (ROA)	16.27%	16.48%	18.46%	12.83%	20.75%	15.22%
Return on Invested Capital (ROIC)	78.76%	84.52%	63.32%	50.51%	629.06%	159.91%
Return on Capital Employed (ROCE)	26.40%	26.90%	26.70%	22.00%	32.00%	24.90%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	5.74%	7.47%	6.58%	3.98%	4.29%	5.66%
FCF Yield	5.40%	7.27%	9.61%	-3.06%	5.48%	8.50%
Buyback Yield / Dilution	-1.12%	-1.85%	-9.84%	-2.14%	-3.32%	-1.46%

SEC Filings: 10-K · 10-Q